We are concerned about the loss of investor confidence which debt schemes face given significant write-downs/offs on exposures to stressed corporates. While we are hopeful of the market share re-gain, we believe the recovery will take longer than street expectations. Lastly despite our positive bias towards Nippon Life as sole promoter, increased credibility to raise HNI/institutional capital, and valuation discount (26.8% on FY21E P/E) to HDFCAMC, we retain NEUTRAL with an unchanged TP of Rs 321 (30x Dec-21E NOLPAT + cash). NAM printed a broadly in-line 3QFY20, with core operating profits of Rs 1.36bn (+24.7/0.2% YoY/QoQ, 2.3% miss). Higher other income (79.7% beat!) drove profitability to Rs 1.49bn (+36.3/21.7% YoY/QoQ, 13.8% beat).